Literature DB >> 12626202

Cell adhesion and tissue factor upregulation in oxygenators used during coronary artery bypass grafting are modified by the Corline Heparin Surface.

M Johnell1, G Elgue, S Thelin, R Larsson, A Siegbahn.   

Abstract

OBJECTIVE: Cardiopulmonary bypass (CPB) is associated with inflammatory response and activation of coagulation. We investigated the influence of a new heparin surface on the activation of cells retrieved from oxygenators used during coronary artery bypass grafting (CABG).
DESIGN: Sixty patients undergoing CABG with CPB were randomly assigned to either uncoated or completely Corline Heparin Surface (CHS)-coated circuits with one of three different levels of systemic heparin: standard, high or low. At end of surgery adhered cells were retrieved from the oxygenators and cell count, tissue factor (TF)- and CD11b-expression on monocytes and monocytic TFmRNA were analysed.
RESULTS: The heparin coating of the oxygenator prevented adhesion of granulocytes, monocytes and platelets. TF-expression on monocytes from the oxygenators was significantly higher than on circulating cells in all groups. Monocytes from the uncoated oxygenators showed low levels of TF-expression with high levels of TFmRNA. The coated group with high level of heparin showed higher surface-expression of TF with low levels of TFmRNA.
CONCLUSION: The CHS was most biocompatible with the standard level of heparin used during CABG whereas elevation of systemic heparin rather increased the activation and TF upregulation in monocytes from oxygenators.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12626202     DOI: 10.1080/140174302762659076

Source DB:  PubMed          Journal:  Scand Cardiovasc J        ISSN: 1401-7431            Impact factor:   1.589


  1 in total

1.  A new method for incorporating functional heparin onto the surface of islets of Langerhans.

Authors:  Sanja Cabric; Torsten Eich; Javier Sanchez; Bo Nilsson; Olle Korsgren; Rolf Larsson
Journal:  Tissue Eng Part C Methods       Date:  2008-06       Impact factor: 3.056

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.